We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Celtaxsys restructures, enhances operational focus

Celtaxsys restructures, enhances operational focus

September 16, 2013
CenterWatch Staff

Celtaxsys, an Atlanta-based pharmaceutical discovery and development company, has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis.

Dr. Michael Hanley has retired as chief executive officer and chairman, and Dr. Brett Premack has stepped down as chief technology officer. Dr. H. Daniel Perez, a member of the Celtaxsys board and former chief executive officer of Berlex Biosciences and Presidio Pharmaceuticals, is serving as chairman.

Ed Philpot, M.D., now is chief medical officer. Philpot has been chair of the medical advisory panel for the CTX-4430 development program for the past year and was formerly chief medical officer at Smith & Nephew and previously executive director of pulmonary disease and immuno-inflammation at GlaxoSmithKline, where he led several late stage clinical development programs.

United States Drug Sponsors

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing